Malta’s AquaBioTech Group has signed a three year contract with an option for a three year extension for clinical research on aquatic vaccines with Norway’s PHARMAQ AS.
The two companies have been collaborating for over a year already, but this new agreement will see a significantly larger amount of scientific research and development work being undertaken in Malta.
Clinical research will focus around the development and documentation of aquatic vaccines for fish grown in Mediterranean aquaculture, but the facility also offers research opportunities with other warm water species.
